Compare BridgeBio Pharma Inc (BBIO) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Altria Group Inc — how do they compare? BridgeBio Pharma Inc trades at $82.71 (market cap $16.46B), while Altria Group Inc trades at $71.04 (market cap $117.16B). The key difference: Altria Group Inc is far larger — about 7.1× BridgeBio Pharma Inc's market cap, and Altria Group Inc pays a 6.04% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MO | |
|---|---|---|
Market Cap | $16.46B | $117.16B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $74.55 |
52-Week Low | $44.81 | $54.72 |
Enterprise Value | $18.02B | $138.23B |
Dividend Yield | — | 6.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
MO trades at $71.87, up 0.14% today, with a neutral technical signal and bullish moving averages. The company reported a net income margin of 39.52% for 2025, with recent earnings beating expectations in Q1 2026. Strong cash flow from operations of $9.29B supports its dividend, with a recent $1.06 payment declared. Analyst consensus is bullish with a $71.00 price target.
Outlook remains stable with defensive qualities highlighted by media, but risks include high debt levels and regulatory pressures. The stock offers a high yield and pricing power, though revenue trends show slight volatility. Investment appeal centers on dividend sustainability and cash flow generation amid a challenging industry backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
